Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY) and Genocea Biosciences (GNCA).
Incyte (INCY)
J.P. Morgan analyst Cory Kasimov assigned a Hold rating to Incyte on February 9 and set a price target of $98.00. The company’s shares closed last Thursday at $85.32.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.3% and a 55.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $97.00, which is a 12.7% upside from current levels. In a report issued on February 9, Mizuho Securities also maintained a Hold rating on the stock with a $95.00 price target.
See today’s analyst top recommended stocks >>
Genocea Biosciences (GNCA)
Needham analyst Chad Messer maintained a Buy rating on Genocea Biosciences today and set a price target of $6.00. The company’s shares closed last Thursday at $3.45.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 19.4% and a 55.9% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Ionis Pharmaceuticals, and Autolus Therapeutics.
Genocea Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
